



Sutent[®] (sunitinib malate) – New indication

- On November 16, 2017, the [FDA announced](#) the approval of [Sutent \(sunitinib malate\)](#) for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.
 - Sutent is also approved for the treatment of gastrointestinal stromal tumor, advanced RCC, and advanced pancreatic neuroendocrine tumors.
- The approval of Sutent for this new indication was based on a placebo-controlled trial of 615 patients with high risk of recurrent RCC following nephrectomy. The major efficacy outcome measure was disease-free survival (DFS).
 - The median DFS was statistically significantly greater with Sutent vs. placebo [6.8 years vs. 5.6 years, respectively; $p = 0.03$, HR = 0.76 (95% CI: 0.59, 0.98)].
 - The 5 year DFS rate was 59.3% with Sutent vs. 51.3% with placebo.
 - At the time of the DFS analysis, overall survival data were not mature with 141/615 (23%) patient deaths.
- Sutent carries a boxed warning for hepatotoxicity.
- The recommended dose of Sutent for the adjuvant treatment of RCC is 50 mg orally once daily, 4 weeks on treatment, followed by 2 weeks off for nine 6-week cycles.
- Refer to the Sutent drug label for dosing recommendations for other indications.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.